Eton Pharma acquires U.S. rights to PKU GOLIKE for $2.2M upfront plus milestones and 30% royalty

Eton Pharmaceuticals, Inc.

Acquired U.S. rights to PKU GOLIKE for $2.2M upfront, up to $2M milestones, and 30% royalty on net sales.
PKU GOLIKE targets phenylketonuria (PKU) in an estimated $100M U.S. medical formula market.
Deal expected to be accretive to 2024 earnings; peak sales forecast >$10M annually.
Also acquired U.S. rights to line extensions for tyrosinemia, homocystinuria (launch 2025/2026) and right of first negotiation for RLF-OD032.
Product complements Eton's metabolic franchise; promoted by existing sales force targeting metabolic geneticists.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.